US20020187205A1 - Multi-vitamin and mineral supplements for women - Google Patents
Multi-vitamin and mineral supplements for women Download PDFInfo
- Publication number
- US20020187205A1 US20020187205A1 US10/207,968 US20796802A US2002187205A1 US 20020187205 A1 US20020187205 A1 US 20020187205A1 US 20796802 A US20796802 A US 20796802A US 2002187205 A1 US2002187205 A1 US 2002187205A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- total daily
- daily dosage
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940029985 mineral supplement Drugs 0.000 title claims abstract description 72
- 235000020786 mineral supplement Nutrition 0.000 title claims abstract description 72
- 235000020772 multivitamin supplement Nutrition 0.000 title claims abstract description 68
- 229940088594 vitamin Drugs 0.000 claims abstract description 59
- 239000011782 vitamin Substances 0.000 claims abstract description 59
- 229930003231 vitamin Natural products 0.000 claims abstract description 54
- 235000013343 vitamin Nutrition 0.000 claims abstract description 51
- 239000011707 mineral Substances 0.000 claims abstract description 48
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000036541 health Effects 0.000 claims abstract description 15
- 235000016709 nutrition Nutrition 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- 230000004962 physiological condition Effects 0.000 claims abstract description 13
- 238000012423 maintenance Methods 0.000 claims abstract description 6
- 230000008439 repair process Effects 0.000 claims abstract description 4
- 230000026267 regulation of growth Effects 0.000 claims abstract description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 71
- 235000010755 mineral Nutrition 0.000 claims description 46
- 229910052742 iron Inorganic materials 0.000 claims description 42
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 34
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 30
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 26
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 26
- 239000011719 vitamin A Substances 0.000 claims description 26
- 235000019155 vitamin A Nutrition 0.000 claims description 26
- 229940045997 vitamin a Drugs 0.000 claims description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 25
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 24
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 22
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 22
- 150000002506 iron compounds Chemical class 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 21
- 239000011726 vitamin B6 Substances 0.000 claims description 21
- 239000011701 zinc Substances 0.000 claims description 21
- 229910052725 zinc Inorganic materials 0.000 claims description 21
- 229940043430 calcium compound Drugs 0.000 claims description 20
- 150000001674 calcium compounds Chemical class 0.000 claims description 20
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 20
- 239000011715 vitamin B12 Substances 0.000 claims description 20
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 18
- 239000011691 vitamin B1 Substances 0.000 claims description 18
- 229930003316 Vitamin D Natural products 0.000 claims description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 239000011708 vitamin B3 Substances 0.000 claims description 17
- 235000019166 vitamin D Nutrition 0.000 claims description 17
- 239000011710 vitamin D Substances 0.000 claims description 17
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- 229940046009 vitamin E Drugs 0.000 claims description 17
- 229940046008 vitamin d Drugs 0.000 claims description 17
- 150000003752 zinc compounds Chemical class 0.000 claims description 17
- 239000013589 supplement Substances 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 16
- 239000011716 vitamin B2 Substances 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 14
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 11
- 229960005069 calcium Drugs 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 150000002681 magnesium compounds Chemical class 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 239000010949 copper Substances 0.000 claims description 9
- 229910052802 copper Inorganic materials 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 229960003495 thiamine Drugs 0.000 claims description 9
- 229940011671 vitamin b6 Drugs 0.000 claims description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 238000013265 extended release Methods 0.000 claims description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- 206010010957 Copper deficiency Diseases 0.000 claims description 4
- 206010020915 Hypervitaminosis Diseases 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 150000001845 chromium compounds Chemical class 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000005078 molybdenum compound Substances 0.000 claims description 4
- 150000002752 molybdenum compounds Chemical class 0.000 claims description 4
- 208000030212 nutrition disease Diseases 0.000 claims description 4
- 208000019180 nutritional disease Diseases 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 208000000412 Avitaminosis Diseases 0.000 claims description 3
- 206010061291 Mineral deficiency Diseases 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 208000024335 physical disease Diseases 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- OHZCFWMJMWFNFP-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O OHZCFWMJMWFNFP-ZVGUSBNCSA-L 0.000 claims description 2
- XXDVUVPHJGZWQC-QHTZZOMLSA-L (2s)-2-amino-5-hydroxy-5-oxopentanoate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O XXDVUVPHJGZWQC-QHTZZOMLSA-L 0.000 claims description 2
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 claims description 2
- 206010004906 Biotin deficiency Diseases 0.000 claims description 2
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 2
- 206010053155 Epigastric discomfort Diseases 0.000 claims description 2
- 206010016260 Fatty acid deficiency Diseases 0.000 claims description 2
- 239000004277 Ferrous carbonate Substances 0.000 claims description 2
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 2
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 206010021135 Hypovitaminosis Diseases 0.000 claims description 2
- 206010067997 Iodine deficiency Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 206010033685 Pantothenic acid deficiency Diseases 0.000 claims description 2
- 208000002141 Pellagra Diseases 0.000 claims description 2
- 208000005428 Thiamine Deficiency Diseases 0.000 claims description 2
- 208000010011 Vitamin A Deficiency Diseases 0.000 claims description 2
- 206010047612 Vitamin B2 deficiency Diseases 0.000 claims description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 claims description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims description 2
- 206010047631 Vitamin E deficiency Diseases 0.000 claims description 2
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 claims description 2
- 206010047634 Vitamin K deficiency Diseases 0.000 claims description 2
- 206010048259 Zinc deficiency Diseases 0.000 claims description 2
- 229910052586 apatite Inorganic materials 0.000 claims description 2
- 201000007590 ariboflavinosis Diseases 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 208000002894 beriberi Diseases 0.000 claims description 2
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 2
- LMVUZKNUWBMHQY-FJOGWHKWSA-L calcium (Z)-but-2-enedioate 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O LMVUZKNUWBMHQY-FJOGWHKWSA-L 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 229940078480 calcium levulinate Drugs 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019268 ferrous carbonate Nutrition 0.000 claims description 2
- 229960004652 ferrous carbonate Drugs 0.000 claims description 2
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 claims description 2
- 229960002089 ferrous chloride Drugs 0.000 claims description 2
- 239000011640 ferrous citrate Substances 0.000 claims description 2
- 235000019850 ferrous citrate Nutrition 0.000 claims description 2
- 239000011773 ferrous fumarate Substances 0.000 claims description 2
- 235000002332 ferrous fumarate Nutrition 0.000 claims description 2
- 229960000225 ferrous fumarate Drugs 0.000 claims description 2
- 239000004225 ferrous lactate Substances 0.000 claims description 2
- 235000013925 ferrous lactate Nutrition 0.000 claims description 2
- 229940037907 ferrous lactate Drugs 0.000 claims description 2
- 229960001604 ferrous succinate Drugs 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 229940057006 ferrous tartrate Drugs 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 201000006122 hypervitaminosis A Diseases 0.000 claims description 2
- 206010020917 hypervitaminosis D Diseases 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 235000006479 iodine deficiency Nutrition 0.000 claims description 2
- 229960003284 iron Drugs 0.000 claims description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 claims description 2
- 229910000015 iron(II) carbonate Inorganic materials 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 208000004223 riboflavin deficiency Diseases 0.000 claims description 2
- 208000010233 scurvy Diseases 0.000 claims description 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000008359 toxicosis Effects 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 claims description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229940108928 copper Drugs 0.000 claims 1
- 239000007942 layered tablet Substances 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 41
- 238000002360 preparation method Methods 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 description 7
- 229930003451 Vitamin B1 Natural products 0.000 description 7
- 229930003779 Vitamin B12 Natural products 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 7
- 235000010374 vitamin B1 Nutrition 0.000 description 7
- 235000019163 vitamin B12 Nutrition 0.000 description 7
- 235000019158 vitamin B6 Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229930003471 Vitamin B2 Natural products 0.000 description 6
- 229930003537 Vitamin B3 Natural products 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000019164 vitamin B2 Nutrition 0.000 description 6
- 235000019160 vitamin B3 Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 229910052804 chromium Inorganic materials 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000012041 food component Nutrition 0.000 description 5
- 239000011733 molybdenum Substances 0.000 description 5
- 229910052750 molybdenum Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 vitamin A compound Chemical class 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010060800 Hot flush Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000019195 vitamin supplement Nutrition 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960004643 cupric oxide Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000009233 Morning Sickness Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000011642 cupric gluconate Substances 0.000 description 1
- 235000019856 cupric gluconate Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Multi-vitamin and mineral supplements for administration to non-lactating women, which comprise specific regimens of vitamins and minerals tailored to meet the physiological needs of said women. Methods for optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods for formulating a multi-vitamin and mineral supplement that optimize the health of a woman and which comprise identifying life stages which correlate to specific nutritional requirements as a result of varying physiological conditions during a lifetime and selecting specific types and optimal amounts of vitamins and minerals for said life stages.
Description
- This application is a Continuation-in-Part application of U.S. patent application Ser. No. 08/474,071 filed Jun. 7, 1995, which is a Continuation-in-Part application of U.S. patent application Ser. No. 08/262,515 filed Jun. 20, 1994, the entire contents of which are incorporated herein in their entirety.
- 1. Field of the Invention
- The present invention relates to multi-vitamin and mineral supplements, and particularly to multi-vitamin and mineral supplements for administration to women. The supplements are specifically tailored to meet nutritional requirements and maintain a woman's health during specific stages of life. The present invention also relates to methods of optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods of formulating multi-vitamin and mineral supplements for life stages are also encompassed by the present-invention.
- 2. Description of Related Art
- Vitamin and mineral preparations are commonly administered to treat specific medical conditions or as general nutritional supplements. Recent studies have elucidated the important physiological roles played by vitamins and minerals, and established a correlation between deficiencies or excesses of these nutrients and the etiologies of certain disease states in humans. See, e.g., Diplock, “Antioxidant Nutrients and Disease Prevention: An Overview,” Am. J. Clin. Nutr., 53:189-193 (1991); Document Geigy Scientific Tables, 457-497 (Diem and Cemtuer eds., 7th ed., 1975).
- It has further become recognized that various life-stage groups of the human population require different quantities; and types of vitamins and minerals to prevent or alleviate diseases, as well as to maintain general good health. For example, it is known that pregnant women commonly require iron therapy to prevent or treat iron-deficiency anemia.
- Various prior patents have been directed to improving the efficacy of iron supplements for use during pregnancy.
- U.S. Pat. No. 4,994,283, for example, discloses nutritional mineral supplements which include iron and calcium compounds in combination with citrates or tartrates, ascorbates, and fructose. The tendency of calcium to inhibit the bioavailability of iron is said to be reduced in such compositions, so that the conjoint bioavailability of these two minerals is enhanced.
- U.S. Pat. No. 4,431,634 discloses maximization of iron bioavailability in prenatal iron supplements by maintaining the amount of calcium compounds in the supplement at 300 mg or less and the amount of magnesium compounds at 75 mg or less per dosage unit.
- Another approach to the same problem is found in U.S. Pat. No. 4,752,479, wherein a multi-vitamin and mineral dietary supplement is provided which includes (a) one or more divalent dietary mineral components such as calcium or magnesium; and (b) a bioavailable iron component, presenting a controlled release form and adapted to be released in a controlled manner in the gastrointestinal tract.
- U.S. Pat. No. 4,710,387 discloses a nutritional supplement preparation for pregnant and breast-feeding women which contains 10-20% by weight of protein, 16-28% by weight of fat, 43-65% by weight carbohydrates, and at most 3.5% by weight of moisture, minerals, trace elements and vitamins.
- Multi-vitamin and mineral formulations which are directed specifically to woman have been disclosed in prior patents and in the medical literature.
- The Physicians' Desk Reference (PDR) for Nonprescription Drugs, 9th Edition, 718-19 (1988) discloses a complete calcium/vitamin/mineral supplement program formulated for women. The program contains two specific formulas. One formulation is directed to woman between the ages of 14 and 40, and the other formulation is directed to woman over the age of 40. These formulations do not specifically distinguish between the varying physiological states experienced by women throughout the course of their lives. In fact, by providing one formulation for the broad category of woman aged 14-40, this disclosure highlights the need for more specific formulations.
- The Handbook of Nonprescription Drugs, 9th Edition, 447-51, discloses amounts of vitamins and minerals which are optimum for pregnant and lactating women. However, no distinction is drawn between what amounts are optimum for pregnant versus lactating women. Further, there is no identification of specific amounts of vitamins and minerals correlating specifically to any other life stages of women. Moreover, the reference teaches that the prime criteria for optimum nutrition are age, weight, height and sex.
- WO 95/35098 discloses multi-vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women which comprise specific regimens of critical nutritional agents. This reference teaches formulations containing high amounts of iron, zinc and vitamin B1, and low amounts of vitamin B12 and vitamin B6.
- Despite the foregoing efforts to improve vitamin and mineral supplementation for pregnant women, conventional prenatal supplements are not ideally suited for women during other phases of their lives. Moreover, the foregoing efforts to improve vitamin and mineral supplementation for women, in general, have lacked the specificity required for achieving formulations which are truly adapted to meet the physiological needs of woman at various times in their lives. For example, the nutritional needs of lactating women following a pregnancy differ from the nutritional needs of women during pregnancy. The vitamin and mineral requirements for non-lactating and menopausal women also differ from the requirements of pregnant women.
- Conventional nutritional formulations are poorly designed for administration to women during various stages of life in which the physiological requirements of the women vary significantly. As such, the previously disclosed multi-vitamin and mineral formulations do not truly meet the specific needs of women. It would therefore be desirable to provide multi-vitamin and mineral supplements which obviate the deficiencies of known vitamin and mineral products while satisfying the long standing need for such supplements.
- None of the above described references is admitted to be prior art.
- The present invention overcomes the shortcomings of known nutritional supplements by providing multivitamin and mineral supplements which are specifically tailored for administration to woman during various stages of life, and more specifically to lactating, non-lactating, and menopausal women. The formulations of the invention have been found to maximize the benefits of vitamin and mineral supplementation for women by specifically formulating the products to meet the physiological requirements of women during these life stages.
- Moreover, the bioavailability of each vitamin and mineral in a multi-vitamin formulation is affected by the presence of other vitamins and minerals in the formulation, as well as by the amounts of each vitamin and mineral present and the physiological state of the individual using said formulation. Use of the specific formulations of the present invention for the prescribed life stages unexpectedly results in a higher bioavailability of essential nutrients.
- The compositions of the invention include certain essential nutritional components in dosage levels which have been found to optimize the maintenance of a woman's health during each of the noted stages of life. Minerals such as calcium, zinc and iron are dosed (i.e. provided in the supplement) in the form of a corresponding pharmaceutically acceptable compound.
- According to a first aspect of the invention, a multi-vitamin and mineral supplement for administration to a lactating woman is provided. This supplement is specially designed to aid in fulfilling the dietary needs of women who are producing and secreting milk, that is, lactating women. The multi-vitamin and mineral supplement comprises:
- (a) from about 350 mg to about 480 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) from about 400 I.U. to about 600 I.U. of vitamin D;
- (c) from about 400 I.U. to about 8,000 I.U. of Beta carotene, or about 3600 I.U. to about 10,000 I.U. of vitamin A or mixtures thereof;
- (d) from about 9.6 mcg to about 14.4 mcg of vitamin B12;
- (e) from about 8 mg to about 12 mg of vitamin B6;
- (f) from about 15 mg to about 30 mg of vitamin B3;
- (g) from about 2.7 mg to about 4.0 mg of vitamin B2;
- (h) from about 3.2 mg to about 4.6 mg of vitamin B1;
- (i) from about 24 I.U. to about 36 I.U. of vitamin E;
- (j) from about 10 mg to about 30 mg of elemental iron, dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) from about 20 mg to about 30 mg of elemental zinc, dosed in the form of a pharmaceutically acceptable zinc compound.
- A multi-vitamin and mineral supplement for administration to a non-lactating woman is also provided by the invention. This supplement is designed to aid in fulfilling the dietary needs of women during the period after puberty and before menopause who are neither pregnant nor lactating. This formulation comprises:
- (a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
- (c) a total daily dosage of about 2,000 I.U. to about 6,000 I.U. of vitamin A or mixtures thereof;
- (d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
- (e) a total daily dosage of about 8 mg to about 26 mg of vitamin B6;
- (f) a total daily dosage of about 10 mg to about 30 mg of vitamin B3;
- (g) a total daily dosage of about 2.5 mg to about 4.0 mg of vitamin B2;
- (h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
- (i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
- (j) a total daily dosage of about 6 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) a total daily dosage of about 12 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
- A multi-vitamin and mineral supplement for administration to a menopausal woman is also provided. This supplement is specially designed to aid in fulfilling the dietary needs of women during the transitional period marked by the cessation of menses. Menopausal women may be asymptomatic or experience a variety of symptoms including hot flushes. See The Merck Manual of Diagnosis and Therapy 15th edition, 1713-1715. Most menopausal women experience hot flushes for over a year and 25 to 50% experience hot flushes for more than five years. The supplement for menopausal women of the present invention comprises:
- (a) from about 320 mg to about 480 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) from about 320 I.U. to about 480 I.U. of vitamin D;
- (c) from about 250 I.U. to about 5000 I.U. of Beta-carotene, or from about 2,000 I.U. to 6,000 I.U. of vitamin A and mixtures thereof;
- (d) from about 20 mcg to about 30 mcg of vitamin B12;
- (e) from about 2.4 mg to about 3.6 mg of vitamin B6;
- (f) from about 16 mcg to about 24 mg of vitamin B3;
- (g) from about 1.3 mg to about 2.0 mg of vitamin B2;
- (h) from about 1.2 mg to about 2.8 mg of vitamin B1;
- (i) from about 7 mg to about 11 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound;
- (k) from about 16 mg to about 24 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound;
- (l) from about 40 mcg to about 60 mcg of elemental molybdenum in the form of a pharmaceutically acceptable molybdenum compound;
- (m) from about 80 mcg to about 120 mcg of elemental chromium dosed in the form of a pharmaceutically acceptable chromium compound.
- A method for optimizing the health of a woman is also included in the present invention. The method comprises administering to said woman a multi-vitamin and mineral supplement comprising vitamins and minerals in amounts adjusted according to varying physiological conditions of said woman over a lifetime.
- A method for formulating a multi-vitamin and mineral supplement which optimizes the health of a woman is also provided. This method comprises:
- (a) identifying a life stage of a woman which presents specific nutritional requirements as a result of varying physiological conditions over a lifetime;
- (b) selecting specific vitamins and minerals according to the varying physiological conditions;
- (c) determining optimal amounts of each vitamin and mineral according to varying physiological conditions of said woman over a lifetime; and
- (d) preparing a multi-vitamin and mineral supplement containing the determined optimal amounts of each vitamin and mineral of step (c).
- Thus, the invention provides the above-described multi-vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women, as well as methods both for optimizing the health of women and for preparing formulations for same. In contrast to conventional vitamin and mineral products, the formulations of the invention comprise specific regimens of critical nutritional agents, in order to better meet the physiological requirements of women and maintain good health throughout life.
- As used herein, “non-lactating woman” refers to a woman who has experienced puberty, but has not experienced menopause, and who is not lactating and not pregnant.
- “Nutrient” refers to any substance in a human or other living organism which regulates the growth, maintenance, and repair of body tissue, as well as any substance which provides energy or structural material to the body.
- “Essential nutrient” refers to any nutrient which is not produced by a human or other living organism and thus must be obtained from an external source.
- “Body tissue”, refers to any substance in a human or other living organism which is composed of the cells of said human or other organism, respectively.
- “Total daily dosage” refers to the amount of any nutrient formulated for administration during any 24 hour period of time.
- “AM dose” refers to any dose of a multi-vitamin and mineral supplement formulated for administration in the morning hours, and likewise, “PM dose” refers to any dose of a multi-vitamin and mineral supplement formulated for administration in the afternoon, evening or nighttime hours.
- “Life stage” refers to a specific period of time during the course of an individual's life.
- The invention provides multi-vitamin and mineral supplements which are tailored for women at different life stages, and specifically for administration to lactating, non-lactating, and menopausal women. The formulations of the invention include certain essential nutritional components in dosage levels which have been found to optimize the maintenance of a woman's health during each of these stages of life.
- According to a first aspect of the invention, a multi-vitamin and mineral supplement for administration to a lactating woman is provided, which comprises:
- (a) from about 320 mg to about 480 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) from about 400 I.U. to about 600 I.U. of vitamin D;
- (c) from about 400 I.U. to about 8000 I.U. of Beta-carotene, or about 3600 I.U. to about 10,000 I.U. of vitamin A or mixtures thereof;
- (d) from about 9.6 mcg to about 14.4 mcg of vitamin B12;
- (e) from about 8 mg to about 12 mg of vitamin B6;
- (f) from about 15 mg to about 30 mg of vitamin B3;
- (g) from about 2.7 mg to about 4 mg of vitamin B2;
- (h) from 3.2 mg to about 4.8 mg of vitamin B1;
- (i) from about 24 I.U. to about 36 I.U. of vitamin E;
- (j) from about 10 mg to about 30 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) from about 20 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
- A particularly preferred multi-vitamin and mineral supplement for lactating women also includes from about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound and about 95 mg to about 145 mg of vitamin C.
- A multi-vitamin and mineral supplement for administration to a non-lactating woman is also provided by the invention. This supplement is designed to specifically aid in fulfilling the dietary needs of women during the period after puberty and before menopause who are neither pregnant nor lactating. The invention may be used by a non-lactating woman who has never given birth or a non-lactating woman who has given birth one or more times. The formulation comprises:
- (a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
- (c) a total daily dosage of about 2,000 I.U. to about 5,400 I.U. of vitamin A or mixtures thereof;
- (d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
- (e) a total daily dosage of about 8 mg to about 26 mg of vitamin B6;
- (f) a total daily dosage of about 15 mg to about 30 mg of vitamin B3;
- (g) a total daily dosage of about 2.7 mg to about 4.0 mg of vitamin B2;
- (h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
- (i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
- (j) a total daily dosage of about 10 mg to about 30 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) a total daily dosage of about 12 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
- Preferably, the multi-vitamin and mineral supplement for non-lactating women also includes from about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound and about 95 mg to about 300 mg of vitamin C, or more preferably from about 180 mg to about 220 mg of a pharmaceutically acceptable magnesium compound, from about 180 to about 220 mg of vitamin C, from about 0.040 mg to about 0.060 mg of a pharmaceutically acceptable molybdenum compound, and from about 0.080 mg to about 0.120 mg of a pharmaceutically acceptable chromium compound.
- Even more preferably, the present invention includes a multi-vitamin and mineral supplement for administration to a non-lactating woman which comprises:
- (a) a total daily dosage of about 180 mg to about 220 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) a total daily dosage of about 380 I.U. to about 420 I.U. of vitamin D;
- (c) a total daily dosage of about 4,500 I.U. to about 5,500 I.U. of vitamin A or mixtures thereof;
- (d) a total daily dosage of about 0.010 mg to about 0.030 mg of vitamin B12;
- (e) a total daily dosage of about 16 mg to about 24 mg of vitamin B6;
- (f) a total daily dosage of about 17 mg to about 25 mg of vitamin B3;
- (g) a total daily dosage of about 3.0 mg to about 3.8 mg of vitamin B2;
- (h) a total daily dosage of about 2.7 mg to about 3.5 mg of vitamin B1;
- (i) a total daily dosage of about 64 I.U. to about 95 I.U. of vitamin E;
- (j) a total daily dosage of about 10 mg to about 30 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) a total daily dosage of about 14 mg to about 25 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
- Most preferably, the present invention includes a multi-vitamin and mineral supplement for administration to a non-lactating woman which comprises:
- (a) a total daily dosage of about 190 mg to about 210 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) a total daily dosage of about 395 I.U. to about 405 I.U. of vitamin D;
- (c) a total daily dosage of about 4,750 I.U. to about 5,250 I.U. of vitamin A or mixtures thereof;
- (d) a total daily dosage of about 0.016 mg to about 0.024 mg of vitamin B12;
- (e) a total daily dosage of about 18 mg to about 22 mg of vitamin B6;
- (f) a total daily dosage of about 18 mg to about 22 mg of vitamin B3;
- (g) a total daily dosage of about 3.2 mg to about 3.6 mg of vitamin B2;
- (h) a total daily dosage of about 2.8 mg to about 3.2 mg of vitamin B1;
- (i) a total daily dosage of about 70 I.U. to about 80 I.U. of vitamin E;
- (j) a total daily dosage of about 15 mg to about 24 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) a total daily dosage of about 14 mg to about 25 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
- A multi-vitamin and mineral supplement for administration to a menopausal woman is also provided, which comprises:
- (a) from about 320 mg to about 480 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) from about 320 I.U. to about 480 I.U. of vitamin D;
- (c) from about 250 I.U. to about 750 I.U. of Beta-carotene or from about 3,600 I.U. to about 5,400 I.U. of vitamin A and mixtures thereof;
- (d) from about 20 mcg to about 30 mcg of vitamin B12;
- (e) from about 2.4 mg to about 3.6 mg of vitamin B6;
- (f) from about 16 mg to about 24 mg of vitamin B3;
- (g) from about 1.3 mg to about 2.0 mg of vitamin B2;
- (h) from about 1.2 mg to about 1.8 mg of vitamin B1;
- (i) from about 70 I.U. to about 110 I.U. of vitamin E;
- (j) from about 7 mg to about 11 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound;
- (k) from about 16 mg to about 24 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound;
- (l) from about 40 mcg to about 60 mcg of element molybdenum dosed in the form of a pharmaceutically acceptable molybdenum compound; and
- (m) from about 80 mcg to about 120 mcg of elemental chromium dosed in the form of a pharmaceutically acceptable chromium compound.
- A particularly preferred multi-vitamin and mineral supplement for menopausal women also includes about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound.
- A method for optimizing the health of a woman is also provided in the present invention. The method comprises administering to said woman a multi-vitamin and mineral supplement comprising vitamins and minerals in amounts adjusted according to varying physiological conditions of said woman over a lifetime.
- Preferably, the method comprises administering to said non-lactating woman a multi-vitamin and mineral supplement comprising:
- (a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
- (b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
- (c) a total daily dosage of about 2,000 I.U. to about 5,400 I.U. of vitamin A or mixtures thereof;
- (d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
- (e) a total daily dosage of about 8 mg to about 26 mg of vitamin B6;
- (f) a total daily dosage of about 20 mg to about 30 mg of vitamin B3;
- (g) a total daily dosage of about 2.7 mg to about 4.0 mg of vitamin B2;
- (h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
- (i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
- (j) a total daily dosage of about 6 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
- (k) a total daily dosage of about 12 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
- A method for formulating a multi-vitamin and mineral supplement which optimizes the health of a woman is also included. This method comprises:
- (a) identifying a life stage of a woman which presents specific nutritional requirements as a result of varying physiological conditions over a lifetime;
- (b) selecting specific vitamins and minerals according to the varying physiological conditions;
- (c) determining optimal amounts of each vitamin and mineral according to the varying physiological conditions of said woman over a lifetime; and
- (d) preparing a multi-vitamin and mineral supplement containing the determined optimal amounts of each vitamin and mineral of step (c).
- It will be noted that the formulations vary in the critical nutritional agents included and amounts thereof. For example, because calcium is essential for the production of milk, levels of calcium are higher for administration to lactating women than in the non-lactating and menopausal formulations. As menopausal women do not lose iron like women with menstrual cycles, the amount of iron in the menopausal formulation is reduced greatly in comparison to the formulations for lactating and non-lactating women. Molybdenum and chromium are added to the menopausal formulation because these agents are believed to assist the immune system, which is a useful therapy in older women.
- Various side effects may be associated with the use of certain vitamins and minerals at various times in some individuals. For example, women who are pregnant and experiencing morning sickness can not tolerate excessive levels of iron. However, women who are not pregnant are able to tolerate higher levels of iron and it may be advantageous for them to take a formulation with more iron. Other side effects are experienced when using niacin, magnesium and other such vitamins and minerals, without limitation. By recognizing the correlation between different life stages of women and the amount of each vitamin and mineral which may induce side effects, the present invention addresses the problem of providing optimal supplementation of vitamins and minerals while eliminating or at least minimizing said side effects. Accordingly, the present invention is designed to minimize adverse effects often experienced by women when taking vitamin and mineral supplements while providing the optimal amount of vitamins and minerals.
- The present invention is contemplated for use by women of varying physical conditions, without limitation, including normal, healthy women and women with a physical disorder, vitamin or mineral deficiency, or a nutritional disorder. Non-limiting exemplary vitamin deficiencies include vitamin A deficiency, hypervitaminosis A, vitamin D deficiency and dependancy, hypervitaminosis D, vitamin E deficiency and toxicity, vitamin K deficiency, hypervitaminosis K, essential fatty acid deficiency, thiamine deficiency, riboflavin deficiency, niacin deficiency, vitamin B6 deficiency and dependency, biotin deficiency and dependency, pantothenic acid deficiency, carnitine deficiency and vitamin C deficiency. Non-limiting exemplary mineral deficiencies include phosphate depletion, iodine deficiency, fluorine deficiency, zinc deficiency, disturbances in copper metabolism, acquired copper deficiency, acquired copper toxicosis, inherited copper deficiency and inherited copper toxicosis.
- Useful pharmaceutically acceptable calcium compounds include, without limitation, any of the well-known calcium supplements such as calcium carbonate, calcium phosphate, calcium citrate, calcium sulfate, calcium oxide, calcium hydroxide, calcium apatite, calcium citrate-maleate, calcium lactate, calcium levulinate and the like. Preferably, calcium compounds selected from the group consisting of calcium carbonate, calcium sulfate, and mixtures thereof are employed.
- Useful pharmaceutically acceptable zinc compounds include, without limitation, zinc sulfate, zinc chloride, and zinc oxide, with zinc sulfate being preferred.
- The pharmaceutically acceptable iron compound may be chosen from any of the well-known iron II (ferrous) or iron III (ferric) supplements, such as ferrous fumarate, ferrous sulfate, carbonyl iron, ferrous glucomate, ferrous chloride, ferrous lactate, ferrous tartrate, ferrous succinate, ferrous glutamate, ferrous citrate, ferrous pyrophosphate, ferrous cholinisocitrate, ferrous carbonate, iron-sugarcarboxylate complexes and the like, without limitation.
- Preferably, the iron compound comprises a pharmaceutically acceptable iron compound contained in a pharmaceutically acceptable film forming material which permits release of the iron in the stomach of a woman administered the supplement. The iron may or may not be coated. Suitable coatings include, without limitation, any material known in the art for forming enteric, controlled release, or sustained release coatings, such as cellulose ethers including hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, and carboxymethylcellulose; cellulose esters such as cellulose acetate, cellulose acetate phthalate, and cellulose nitrate; acrylate and methacrylate copolymers; and the like. The coated iron compound has been found to provide increased iron bioavailability by minimizing interaction between the iron compound and divalent cations such as calcium in the nutritional supplement. Release of the iron in the intestine also minimizes stomach upset. More preferably, the iron is in the coating and is released in the stomach.
- It is also possible in the present formulations to combine various forms of extended release particles or coatings along with immediate release particles or coatings to deliver the various vitamins and mineral supplements over various rates of release, without limitation. For example, certain agents such as thiamine, niacinamide, pyridoxine, ascorbic acid, folic acid, iron and riboflavin could be released over an extended period of time from two hours up to 24 hours while other agents such as beta-carotene, vitamin A, vitamin D3, vitamin B12, biotin, pantothenic acid, copper, zinc, magnesium, potassium, iodine, chromium, molybdenum and selenium can be administered as immediate release. The ability to obtain extended and immediate release characteristics is performed using well known procedures and techniques available to the ordinary skilled artisan.
- The multi-vitamin and mineral supplements-of the invention may include additional nutritional components well-known in the art. For example, the supplements may include elemental magnesium dosed in the form of one or more pharmaceutically acceptable magnesium compounds, without limitation, such as magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide, and magnesium sulfate. Magnesium stearate is a preferred form of the compound. The formulations may also include vitamin C, from about 0.1 mg to about 1 mg of folic acid, from 1 mg to about 3 mg of copper, and from about 0.05 mg to about 0.25 mg of iodine. Other nutritional agents well-known in the art may be included as desired.
- In a preferred embodiment of the formulations, the optional vitamin C and folic acid nutritional components are coated to provide controlled release of these agents. The techniques and materials discussed above that are utilized to coat iron are preferred.
- Pharmaceutically acceptable copper compounds include, without limitation, cupric oxide, cupric sulfate, or cupric gluconate, with cupric oxide being preferred. Preferred pharmaceutically acceptable iodine compounds include sodium or potassium iodide, with potassium iodide being most preferred.
- The vitamins in the formulation may be provided in any source, without limitation. The amounts shown for each vitamin and mineral indicate the actual vitamin and mineral amounts, in milligrams (mg), in the formulations regardless of source, except where otherwise indicated. Vitamin A may be provided in any source, such as a preformed vitamin A compound or a vitamin A precursor, or any combination thereof. The amount of vitamin A in the formulations is expressed as an International Unit (I.U.) which is a measure of vitamin activity. Therefore, the indicated amounts for vitamin A refer to any amount of any precursor or preformed vitamin A compound, from any source whatsoever, which would result in the indicated amount of vitamin A activity in the body. The ability to determine such amounts and achieve formulations containing same is performed using well known procedures and techniques available to the ordinary skilled artisan.
- The nutritional supplements of the invention may be provided in any suitable dosage form known in the art, without limitation. For example, the compositions may be incorporated into tablets, powders, granules, beads, chewable lozenges, capsules, liquids, or similar conventional dosage forms, using conventional equipment and techniques known in the art. Tablet dosage forms are preferred.
- Furthermore, the dosage form can be in the form of a bi-layer tablet composed of at least one extended-release layer and at least one immediate-release layer. Also, the bi-layer tablet can be coated for ease of administration or can be enteric coated to reduce any gastric irritation and the unpleasant “burping” produced by the vitamins and minerals. Also, multi-particulate design of extended release and immediate-release components can be enteric coated and compressed into a tablet or filled into hard or soft gelatin capsules.
- When preparing dosage forms incorporating the compositions of the invention, the nutritional components are normally blended with conventional excipients such as binders, including gelatin, pregelatinized starch, and the like; lubricants, such as hydrogenated vegetable oil, stearic acid, and the like; diluents, such as lactose, mannose, and sucrose; disintegrants, such as carboxymethyl cellulose and sodium starch glycolate; suspending agents, such as povidone, polyvinyl alcohol and the like; absorbent, such as silicon dioxide; preservatives, such as methylparaben, propylparaben, and sodium benzoate; surfactants, such as sodium lauryl sulfate, polysorbate 80, and the like; and colorants, such as F.D. & C dyes and lakes.
- For preparing compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be used which are either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, and cachets. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compounds. In the tablet the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 or 10 to about 90 percent of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, coca butter, and the like. The term “preparation” is intended to include the formulation of the active compounds with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be used a solid dosage forms suitable for oral administration. Liquid form preparations include solutions, suspensions, and emulsions. As an example, water or water/propylene glycol solutions for parenteral injection may be used. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions. These particular solid form preparations are most conveniently provided in unit dose form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as with a syringe, teaspoon, or other volumetric container. When multiple liquid doses are so prepared, it is preferred to maintain the unused portion of said liquid doses at low temperature (i.e., under refrigeration) in order to retard possible decomposition.
- The solid and liquid forms may contain, in addition to the active addition to the material, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. The liquid utilized for preparing the liquid form preparation may be water, isotonic water, ethanol, glycerine, propylene glycol, and the like as well as mixtures thereof. Naturally, the liquid utilized will be chosen with regard to the route of administration, for example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.
- Preferably, the preparations are in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active components. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any of these in packaged form.
- The quantity of active compound in a unit dose of preparation may be varied according to the particular application and the potency of the active ingredients.
- Determination of the proper dosage for a particular situation is well within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day if desired or at one time, morning, afternoon, or night as well as biphasic, triphasic, etc. Moreover, the portion administered in one dose during a day need not be equal to all or any other doses administered during a day.
- For example,, if the total daily dosage is divided into two different doses, such as an AM and a PM dose, then one vitamin, such as vitamin B6, may be present in a lesser amount in the AM dose than in the PM dose. Several or all of the vitamins and/or minerals may be treated in such a manner. The amount of a vitamin and mineral in each dose is determined as the amount which will achieve optimal or maximal efficacy with minimal side effects. The use of such unequal doses during the course of a day may apply to the entire formulation, or any individual vitamin or mineral in said formulation. Moreover, it is believed that the use of unequal doses increases the bioavailability of some or all of the nutrients provided in the formulations.
- Controlled and uncontrolled release formulations, as well as sustained release, extended release, timed release, delayed release and other such formulations, without limitation, are contemplated for use with the present invention.
- Although the products of the invention are preferably intended for administration to humans, it will be understood that the formulation may also be utilized in veterinary therapies for other animals.
- The following examples are given to illustrate the invention but are not deemed to be limiting thereof. All amounts specified in the application are based on milligrams (mg) unless otherwise indicated. The term “I.U.” represents International Units.
- Preparation of Multi-Vitamin and Mineral Supplements
- The following compositions were used to prepare multi-vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women:
TABLE I Component Lactating Non-Lactating Menopausal Calcium, mg 320-480 160-240 320-480 Vitamin D, I.U. 400-600 320-480 320-480 Vitamin B12, mg 0.006-0.015 0.006-0.040 0.020-0.030 Vitamin B6, mg 8-40 8-40 8-40 Vitamin B3, mg 18-30 15-30 10-40 Vitamin B2, mg 2.7-5.0 2.7-5.0 2.7-5.0 Vitamin B1, mg 3.2-4.8 2.6-4.8 1-3 Vitamin E, I.U. 20-40 24-100 70-110 Iron, mg 28-43 6-42 7-11 Zinc, mg 20-30 12-30 10-30 Vitamin C, mg 60-300 60-300 60-300 Molybdenum, mg 0.020-0.030 0.040-0.060 0.040-0.060 Chromium, mg 0.040-0.060 0.080-0.120 0.080-0.120 Vitamin A, I.U. 2,000-10,000 2,000-10,000 2,000- 10,000 Potassium, mg. 40-60 40-60 64-96 Pantothenic 12-18 8-12 8-12 Acid, mg Folic Acid, mg 0.8-1.2 0.8-1.2 0.8-1.2 Biotin, mcg 0.040-0.060 0.240-0.360 0.240-0.360 Copper, mg 1.6-2.4 1.6-2.4 1.6-2.4 Iodine, mg 0.120-.180 0.120-0.180 0.120-0.180 Magnesium, mg 160-240 160-240 160-240 - Tablets incorporating the above formulations were prepared using conventional methods and materials known in the pharmaceutical art. The resulting nutritional supplement tablets were recovered and stored for future use.
- The following compositions were used to prepare multi-vitamin and mineral supplements for administration to lactating, non-lactating and menopausal women.
TABLE II Component Lactating Non-Lactating Menopausal Calcium, mg 400 200 400 Vitamin D, I.U. 500 400 400 Vitamin B12, mg 0.012 0.020 .025 Vitamin B6, mg 10 20 3 Vitamin B3, mg 25 20 20 Vitamin B2. mg 3.4 3.4 1.7 Vitamin B1, mg 4.0 3.0 1.5 Vitamin E. I.U. 30 75 90 Iron, mg 36 18 9 Zinc, mg 25 15 20 Vitamin C, mg 120 200 240 Potassium, mg — 25 80 Pantothenic Acid, mg 15 10 10 Folic Acid, mg 1.0 1.0 0.5 Biotin. mg 0.050 0.03 0.300 Cooper, mg 2 2 2 Iodide, mg 0.150 0.150 0.150 Magnesium, mg 200 200 200 - The invention being thus described, it will be apparent that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be within the scope of the appended claims.
Claims (43)
1. A multi-vitamin and mineral supplement for administration to a non-lactating woman, which comprises:
(a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
(b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
(c) a total daily dosage of about 2,000 I.U. to about 10,000 I.U. of vitamin A or mixtures thereof;
(d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
(e) a total daily dosage of about 8 mg to about 30 mg of vitamin B6;
(f) a total daily dosage of about 10 mg to about 40 mg of vitamin B3;
(g) a total daily dosage of about 2.7 mg to about 5.0 mg of vitamin B2;
(h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
(i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
(j) a total daily dosage of about 6 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
(k) a total daily dosage of about 5 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
2. The multi-vitamin and mineral supplement of claim 1 , wherein the pharmaceutically acceptable calcium compound is selected from the group consisting of calcium carbonate, calcium phosphate, calcium citrate, calcium sulfate, calcium oxide, calcium hydroxide, calcium apatite, calcium citrate-maleate, calcium lactate, calcium levulinate and the like.
3. The multi-vitamin and mineral supplement of claim 1 , which further comprises from about 100 mg to about 500 mg of a pharmaceutically acceptable magnesium compound.
4. The multi-vitamin and mineral supplement of claim 3 , wherein the pharmaceutically acceptable magnesium compound is selected from the group consisting of magnesium hydroxide, magnesium sulfate, magnesium oxide, magnesium stearate, and magnesium carbonate.
5. The multi-vitamin and mineral supplement of claim 1 , wherein the pharmaceutically acceptable iron compound is selected from the group consisting of ferrous fumarate, ferrous sulfate, carbonyl iron, ferrous glucomate, ferrous chloride, ferrous lactate, ferrous tartrate, ferrous succinate, ferrous glutamate, ferrous citrate, ferrous pyrophosphate, ferrous cholinisocitrate, ferrous carbonate, iron-sugar-carboxylate complexes and the like, coated with a pharmaceutically acceptable film forming material which permits release of the iron in the intestine of a woman administered the supplement.
6. The multi-vitamin and mineral supplement of claim 5 , wherein the pharmaceutically acceptable iron compound is in the form of an extended release iron to be released over a two to twenty-four hour period of time.
7. The multi-vitamin and mineral supplement of claim 1 , wherein a nutrient selected from the group consisting of vitamin B1, vitamin B3, vitamin B6, vitamin C, riboflavin and mixtures thereof is formulated for release over an extended period of time.
8. The multi-vitamin and mineral supplement of claim 1 , wherein a nutrient selected from the group consisting of folic acid, niacinamide, vitamin A, vitamin E, vitamin D3, vitamin B12, biotin, pantothenic acid, copper, zinc, magnesium and mixtures thereof is formulated for immediate release.
9. The multi-vitamin and mineral supplement of claim 1 , wherein the vitamin is a lipid-soluble vitamin.
10. The multi-vitamin and mineral supplement of claim 1 , wherein the vitamin is a water-soluble vitamin.
11. The multi-vitamin and mineral supplement of claim 10 , wherein the water-soluble vitamin is formulated for release over an extended period of time ranging from about six hours to about twenty-four hours.
12. The multi-vitamin and mineral supplement of claim 1 , wherein a first nutrient selected from the group consisting of thiamine, niacinamide, pyridoxine, ascorbic acid, folic acid, iron, riboflavin and mixtures thereof is formulated for release over an extended period of time ranging from about six hours to about twenty-four hours, and wherein a second nutrient selected from the group consisting-of vitamin A, vitamin D3, vitamin B12, biotin, pantothenic acid, copper, zinc, magnesium, potassium iodine and mixtures thereof is formulated for immediate release.
13. The multi-vitamin and mineral supplement of claim 1 , wherein the pharmaceutically acceptable zinc compound is selected from the group consisting of zinc oxide, zinc sulfate, and zinc chloride.
14. The multi-vitamin and mineral supplement of claim 1 , further comprising a total daily dosage of about 60 mg to about 300 mg of vitamin C.
15. The multi-vitamin and mineral supplement of claim 1 , further comprising a pharmaceutically acceptable carrier material.
16. The multi-vitamin and mineral supplement of claim 1 , which is administered orally once per day.
17. The multi-vitamin and mineral supplement of claim 1 , wherein the total daily dosage is divided and administered in portions during the day.
18. The multi-vitamin and mineral supplement of claim 1 , wherein the dosage form is in the form of a multi-layer tablet comprising an extended-release layer and an immediate-release layer.
19. The multi-vitamin and mineral supplement of claim 1 , wherein the multi-layered tablet is coated for ease of administration or enteric coated to reduce gastric irritation.
20. The multi-vitamin and mineral supplement of claim 1 , wherein the dosage form is enteric coated and compressed into a tablet or filled into hard or soft gelatin capsules.
21. A multi-vitamin and mineral supplement for administration to a non-lactating woman, which comprises:
(a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
(b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
(c) a total daily dosage of about 2,000 I.U. to about 10,000 I.U. of vitamin A or mixtures thereof;
(d) a total daily dosage of about 0.006 mg to about 0.030 mg of vitamin B12;
(e) a total daily dosage of about 8 mg to about 40 mg of vitamin B6;
(f) a total daily dosage of about 20 mg to about 30 mg of vitamin B3;
(g) a total daily dosage of about 2.7 mg to about 4.0 mg of vitamin B2;
(h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
(i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
(j) a total daily dosage of about 10 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound;
(k) a total daily dosage of about 12 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound; and
(l) a total daily dosage of about 95 to about 300 mg of vitamin C.
22. The multi-vitamin and mineral supplement of claim 21 , which further comprises from about 0.040 mg to about 0.060 mg of a pharmaceutically acceptable molybdenum compound.
23. The multi-vitamin and mineral supplement of claim 21 , which further comprises from about 0.080 mg to about 0.120 mg of a pharmaceutically acceptable chromium compound.
24. A multi-vitamin and mineral supplement for administration to a non-lactating woman, which comprises:
(a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
(b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
(c) a total daily dosage of about 2,000 I.U. to about 10,000 I.U. of vitamin A or mixtures thereof;
(d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
(e) a total daily dosage of about 8 mg to about 40 mg of vitamin B6;
(f) a total daily dosage of about 20 mg to about 30 mg of vitamin B3;
(g) a total daily dosage of about 2.7 mg to about 4.0 mg of vitamin B2;
(h) a total daily dosage of about 1 mg to about 4.8 mg of vitamin B1;
(i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
(j) a total daily dosage of about 6 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound;
(k) a total daily dosage of about 10 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound; and
(l) a total daily dosage of about 60 to about 300 mg of vitamin C; and
(m) from about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound.
25. A method for optimizing the health of a woman, which comprises:
administering to said woman a multi-vitamin and mineral supplement comprising vitamins and minerals in amounts adjusted according to varying physiological conditions of said woman over a lifetime.
26. The method of claim 25 , wherein the vitamins and minerals are selected from the group consisting of a pharmaceutically acceptable calcium compound, vitamin D, vitamin A, B complex vitamins, vitamin E, a pharmaceutically acceptable iron compound, a pharmaceutically acceptable zinc compound and mixtures thereof.
27. The method of claim 25 , wherein said method is for achieving optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects.
28. The method of claim 25 , wherein the woman is a non-lactating woman.
29. The method of claim 28 , wherein the non-lactating woman has never given birth.
30. The method of claim 28 , wherein the non-lactating woman has given birth at least once.
31. The method of claim 25 , wherein the woman is a healthy, normal woman.
32. The method of claim 25 , wherein the woman has a physical disorder.
33. The method of claim 32 , wherein the physical disorder is a nutritional disorder.
34. The method of claim 33 , wherein the nutritional disorder is caused by a vitamin deficiency selected from the group consisting of vitamin A deficiency, hypervitaminosis A, vitamin D deficiency and dependency, hypervitaminosis D, vitamin E deficiency and toxicity, vitamin K deficiency, hypervitaminosis K, essential fatty acid deficiency, thiamine deficiency, riboflavin deficiency, niacin deficiency, vitamin B6 deficiency and dependency, biotin deficiency and dependancy, pantothenic acid deficiency, carnitine deficiency, vitamin C deficiency and mixtures thereof.
35. The method of claim 33 , wherein the nutritional disorder is caused by a mineral deficiency selected from the group consisting of phosphate depletion, iodine deficiency, fluorine deficiency, zinc deficiency, disturbances in copper metabolism, acquired copper deficiency, acquired copper toxicosis, inherited copper deficiency, inherited copper toxicosis and mixtures thereof.
36. The method of claim 28 , wherein the multi-vitamin and mineral supplement is administered to meet nutritional requirements of the non-lactating woman while attaining minimal inducement of side effects.
37. A method for optimizing the health of a non-lactating woman, which comprises:
administering to said non-lactating woman a multi-vitamin and mineral supplement comprising:
(a) a total daily dosage of about 160 mg to about 240 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
(b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
(c) a total daily dosage of about 2,000 I.U. to about 5,400 I.U. of vitamin A or mixtures thereof;
(d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
(e) a total daily dosage of about 8 mg to about 40 mg of vitamin B6;
(f) a total daily dosage of about 10 mg to about 30 mg of vitamin B3;
(g) a total daily dosage of about 2.7 mg to about 5.0 mg of vitamin B2;
(h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
(i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
(j) a total daily dosage of about 6 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
(k) a total daily dosage of about 5 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
38. The method of claim 37 , wherein the multi-vitamin and mineral supplement is administered to meet nutritional requirements of a non-lactating woman while avoiding inducement of side effects.
39. A method for optimizing the health of a non-lactating woman, which comprises:
administering to said non-lactating woman a multi-vitamin and mineral supplement comprising:
(a) a total daily dosage of about 100 mg to about 500 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
(b) a total daily dosage of about 320 I.U. to about 480 I.U. of vitamin D;
(c) a total daily dosage of about 2,000 I.U. to about 10,000 I.U. of,vitamin A or mixtures thereof;
(d) a total daily dosage of about 0.006 mg to about 0.040 mg of vitamin B12;
(e) a total daily dosage of about 8 mg to about 40 mg of vitamin B6;
(f) a total daily dosage of about 10 mg to about 30 mg of vitamin B3;
(g) a total daily dosage of about 2.7 mg to about 5.0 mg of vitamin B2;
(h) a total daily dosage of about 2.6 mg to about 4.8 mg of vitamin B1;
(i) a total daily dosage of about 24 I.U. to about 100 I.U. of vitamin E;
(j) a total daily dosage of about 6 mg to about 42 mg of elemental iron dosed in the form of a pharmaceutically acceptable iron compound; and
(k) a total daily dosage of about 5 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
40. The method of claim 39 , which further comprises from about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound.
41. The method of claim 39 , further comprising a total daily dosage of about 60 mg to about 300 mg of vitamin C.
42. A method for formulating a multi-vitamin and mineral supplement which optimizes the health of a woman, which comprises:
(a) identifying a life stage of a woman which presents specific nutritional requirements as a result of varying physiological conditions over a lifetime;
(b) selecting specific vitamins and minerals according to the varying physiological conditions;
(c) determining optimal amounts of each vitamin and mineral according to the varying physiological conditions of said woman over a lifetime; and
(d) preparing a multi-vitamin and mineral supplement containing the determined optimal amounts of each vitamin and mineral of step (c).
43. The method of claim 42, wherein the woman is a non-lactating woman.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/207,968 US20020187205A1 (en) | 1994-06-20 | 2002-07-31 | Multi-vitamin and mineral supplements for women |
US10/308,051 US20030068372A1 (en) | 1994-06-20 | 2002-12-03 | Nutritional composition |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26251594A | 1994-06-20 | 1994-06-20 | |
US08/474,071 US5869084A (en) | 1994-06-20 | 1995-06-07 | Multi-vitamin and mineral supplements for women |
US12846698A | 1998-08-04 | 1998-08-04 | |
US09/448,744 US6488956B1 (en) | 1994-06-20 | 1999-11-24 | Multi-vitamin and mineral supplements for women |
US10/207,968 US20020187205A1 (en) | 1994-06-20 | 2002-07-31 | Multi-vitamin and mineral supplements for women |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/448,744 Continuation US6488956B1 (en) | 1994-06-20 | 1999-11-24 | Multi-vitamin and mineral supplements for women |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/308,051 Continuation-In-Part US20030068372A1 (en) | 1994-06-20 | 2002-12-03 | Nutritional composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020187205A1 true US20020187205A1 (en) | 2002-12-12 |
Family
ID=27383733
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/448,744 Expired - Fee Related US6488956B1 (en) | 1994-06-20 | 1999-11-24 | Multi-vitamin and mineral supplements for women |
US10/207,968 Abandoned US20020187205A1 (en) | 1994-06-20 | 2002-07-31 | Multi-vitamin and mineral supplements for women |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/448,744 Expired - Fee Related US6488956B1 (en) | 1994-06-20 | 1999-11-24 | Multi-vitamin and mineral supplements for women |
Country Status (1)
Country | Link |
---|---|
US (2) | US6488956B1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040166175A1 (en) * | 2002-12-10 | 2004-08-26 | Giordano John A. | Compositions and methods for nutrition supplementation |
US20080050454A1 (en) * | 2004-08-12 | 2008-02-28 | Giordano John A | Compositions and methods for nutrition supplementation |
US20080057144A1 (en) * | 2006-09-01 | 2008-03-06 | Cathy Beggan | Wake up on time dietary supplement and method of use |
US20080311200A1 (en) * | 2004-09-17 | 2008-12-18 | Bioprogress S.P.A. | Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization |
US20100260836A1 (en) * | 2004-08-12 | 2010-10-14 | Giordano John A | Kits and methods for nutrition supplementation |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
DE102011122250A1 (en) * | 2011-10-24 | 2013-04-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Multiphase system, useful e.g. to treat vitamin deficiency, comprises two different phases/layers comprising first phase/layer of active component comprising iron(II) compound, and second phase/layer of active component comprising vitamin |
US8617617B2 (en) | 2002-12-10 | 2013-12-31 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
US10034899B2 (en) | 2013-11-27 | 2018-07-31 | BioPharmX, Inc. | Solid oral dosage form for breast symptoms |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040037892A1 (en) * | 2001-11-19 | 2004-02-26 | Adrianne Bendich | Dietary composition containing conjugated linoleic acid and calcium for improved health |
US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
PL1732605T3 (en) * | 2004-03-29 | 2019-09-30 | Wyeth Llc | Multi-vitamin and mineral nutritional supplements |
US7785619B2 (en) * | 2004-04-08 | 2010-08-31 | Micro Nutrient, Llc | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US7850987B2 (en) * | 2004-04-08 | 2010-12-14 | Micronutrient, Llc | Nutrient composition(s) and system(s) for individualized, responsive dosing regimens |
WO2005097085A1 (en) * | 2004-04-08 | 2005-10-20 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
US20100255118A1 (en) * | 2007-03-12 | 2010-10-07 | Kanzer Steve H | Oral zinc medicants useful for safely lowering free copper absorption and free copper levels |
US9125844B1 (en) | 2007-09-25 | 2015-09-08 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US7964189B1 (en) | 2007-09-25 | 2011-06-21 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US8535659B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
US8535660B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
RU2540520C2 (en) | 2009-06-24 | 2015-02-10 | Чарльз Н.С. СОПАРКАР | Compositions and methods for improving drug therapy with metal ion dependant agents |
KR20120100964A (en) * | 2009-09-30 | 2012-09-12 | 바이타패스 제네틱스 인코포레이티드 | Cofactors and methods for use for individuals |
ES2362292B1 (en) * | 2009-12-11 | 2012-02-23 | Farmalider, S.A. | ORAL COMPOSITION SOLID PHARMACEUTICAL OR DIETARY SPECIFICALLY INDICATED FOR WOMEN MANAGER. |
US9492421B1 (en) | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
US9629846B1 (en) | 2013-11-14 | 2017-04-25 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US20160038553A1 (en) * | 2014-08-06 | 2016-02-11 | Fairhaven Health, Llc | Nutritional supplement comprising herbal galactagogue |
US10039765B1 (en) | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
US10617700B1 (en) | 2016-02-26 | 2020-04-14 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
US11291683B2 (en) * | 2016-04-01 | 2022-04-05 | Access Business Group International Llc | Bilayer tablets of B vitamins and process for preparing the same |
US11083738B2 (en) | 2017-09-28 | 2021-08-10 | Natals, Inc. | Dietary nutrient compositions |
EP3709994A1 (en) * | 2017-11-14 | 2020-09-23 | Pizeta Pharma S.P.A. | Oral administration form comprising an iron-copper mixture and its use as a food supplement |
JP2022546965A (en) * | 2019-09-05 | 2022-11-10 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Food composition for lactating women |
WO2021043883A1 (en) * | 2019-09-05 | 2021-03-11 | Société des Produits Nestlé S.A. | Food compositions for lactating women |
JP2022546757A (en) * | 2019-09-05 | 2022-11-08 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Food composition for lactating women |
WO2021043882A1 (en) * | 2019-09-05 | 2021-03-11 | Société des Produits Nestlé S.A. | Food compositions for lactating women |
CA3187833A1 (en) * | 2020-09-03 | 2022-03-10 | Dantong WANG | Method for determining dietary food patterns in lactating women |
Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2205111A (en) * | 1936-08-28 | 1940-06-18 | Abbott Lab | Enteric coating |
US2218591A (en) * | 1936-10-10 | 1940-10-22 | Atlantic Coast Fisheries Co | Vitamin preparation |
US2218592A (en) * | 1939-06-17 | 1940-10-22 | Atlantic Coast Fisheries Co | Vitamin preparation and method of making same |
US3125491A (en) * | 1962-04-06 | 1964-03-17 | Chew able hematinic vitamin tablet | |
US3446899A (en) * | 1968-01-25 | 1969-05-27 | Hoffmann La Roche | Vitamin compositions produced by direct compression |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4327077A (en) * | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4431634A (en) * | 1981-12-21 | 1984-02-14 | American Cyanamid Company | Prenatal iron supplements |
US4500515A (en) * | 1981-04-13 | 1985-02-19 | Libby Alfred F | Method for treating alcohol and drug addicts |
US4629625A (en) * | 1984-08-29 | 1986-12-16 | Gaull Gerald E | Human nutritional compositions containing taurine and vitamins and/or minerals |
US4670247A (en) * | 1983-07-05 | 1987-06-02 | Hoffman-Laroche Inc. | Process for preparing fat-soluble vitamin active beadlets |
US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
US4822816A (en) * | 1987-04-10 | 1989-04-18 | Oxycal Laboratories, Inc. | Compositions and methods for administering vitamin C |
US4931441A (en) * | 1988-11-09 | 1990-06-05 | Luitpold Pharmaceuticals, Inc. | Stabilized aqueous leucovorin calcium compositions |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US4945083A (en) * | 1986-06-03 | 1990-07-31 | Jansen Jr Christian J | Safe oral folic-acid-containing vitamin preparation |
US4968716A (en) * | 1987-04-10 | 1990-11-06 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
US5002780A (en) * | 1987-07-31 | 1991-03-26 | Caola Kozmetikai Es Haztartasvegyipari Vallalat | Magnesium salt of a fatty acid acyl lactylate |
US5004613A (en) * | 1987-07-27 | 1991-04-02 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US5070085A (en) * | 1987-04-10 | 1991-12-03 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
US5215750A (en) * | 1991-09-04 | 1993-06-01 | Keane Ii Michael A | L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US5312626A (en) * | 1991-07-01 | 1994-05-17 | Gerhard Gergely | Lozenge or chewable tablet |
US5468506A (en) * | 1992-10-21 | 1995-11-21 | The Procter & Gamble Company | Concentrated bioavailable calcium source |
US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
US5536505A (en) * | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5744161A (en) * | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
US5770217A (en) * | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
US5776504A (en) * | 1995-04-18 | 1998-07-07 | Nutrition 21 | Magnesium taurate for prevention and treatment of pre-eclampsia/eclampsia |
US5869084A (en) * | 1994-06-20 | 1999-02-09 | K-V Pharmaceuticals Co. | Multi-vitamin and mineral supplements for women |
US5965162A (en) * | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
US5985339A (en) * | 1996-11-22 | 1999-11-16 | Kamarei; A. Reza | Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
-
1999
- 1999-11-24 US US09/448,744 patent/US6488956B1/en not_active Expired - Fee Related
-
2002
- 2002-07-31 US US10/207,968 patent/US20020187205A1/en not_active Abandoned
Patent Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2205111A (en) * | 1936-08-28 | 1940-06-18 | Abbott Lab | Enteric coating |
US2218591A (en) * | 1936-10-10 | 1940-10-22 | Atlantic Coast Fisheries Co | Vitamin preparation |
US2218592A (en) * | 1939-06-17 | 1940-10-22 | Atlantic Coast Fisheries Co | Vitamin preparation and method of making same |
US3125491A (en) * | 1962-04-06 | 1964-03-17 | Chew able hematinic vitamin tablet | |
US3446899A (en) * | 1968-01-25 | 1969-05-27 | Hoffmann La Roche | Vitamin compositions produced by direct compression |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4500515A (en) * | 1981-04-13 | 1985-02-19 | Libby Alfred F | Method for treating alcohol and drug addicts |
US4327077A (en) * | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4431634A (en) * | 1981-12-21 | 1984-02-14 | American Cyanamid Company | Prenatal iron supplements |
US4670247A (en) * | 1983-07-05 | 1987-06-02 | Hoffman-Laroche Inc. | Process for preparing fat-soluble vitamin active beadlets |
US4629625A (en) * | 1984-08-29 | 1986-12-16 | Gaull Gerald E | Human nutritional compositions containing taurine and vitamins and/or minerals |
US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
US4945083A (en) * | 1986-06-03 | 1990-07-31 | Jansen Jr Christian J | Safe oral folic-acid-containing vitamin preparation |
US4822816A (en) * | 1987-04-10 | 1989-04-18 | Oxycal Laboratories, Inc. | Compositions and methods for administering vitamin C |
US5070085A (en) * | 1987-04-10 | 1991-12-03 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
US4968716A (en) * | 1987-04-10 | 1990-11-06 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
US5004613A (en) * | 1987-07-27 | 1991-04-02 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US5002780A (en) * | 1987-07-31 | 1991-03-26 | Caola Kozmetikai Es Haztartasvegyipari Vallalat | Magnesium salt of a fatty acid acyl lactylate |
US4931441A (en) * | 1988-11-09 | 1990-06-05 | Luitpold Pharmaceuticals, Inc. | Stabilized aqueous leucovorin calcium compositions |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US5312626A (en) * | 1991-07-01 | 1994-05-17 | Gerhard Gergely | Lozenge or chewable tablet |
US5215750A (en) * | 1991-09-04 | 1993-06-01 | Keane Ii Michael A | L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control |
US5468506A (en) * | 1992-10-21 | 1995-11-21 | The Procter & Gamble Company | Concentrated bioavailable calcium source |
US5965162A (en) * | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
US5536505A (en) * | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
US5869084A (en) * | 1994-06-20 | 1999-02-09 | K-V Pharmaceuticals Co. | Multi-vitamin and mineral supplements for women |
US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5744161A (en) * | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
US5776504A (en) * | 1995-04-18 | 1998-07-07 | Nutrition 21 | Magnesium taurate for prevention and treatment of pre-eclampsia/eclampsia |
US5985339A (en) * | 1996-11-22 | 1999-11-16 | Kamarei; A. Reza | Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products |
US5770217A (en) * | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080254142A1 (en) * | 2002-12-10 | 2008-10-16 | Giordano John A | Compositions and methods for nutrition supplementation |
US20060088603A1 (en) * | 2002-12-10 | 2006-04-27 | Giordano John A | Compositions and methods for nutrition supplementation |
US8617617B2 (en) | 2002-12-10 | 2013-12-31 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
US20040166175A1 (en) * | 2002-12-10 | 2004-08-26 | Giordano John A. | Compositions and methods for nutrition supplementation |
US7390509B2 (en) | 2002-12-10 | 2008-06-24 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US8101587B2 (en) | 2004-08-12 | 2012-01-24 | Everett Laboratories, Inc. | Kits for nutrition supplementation |
US8197855B2 (en) | 2004-08-12 | 2012-06-12 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US20100260836A1 (en) * | 2004-08-12 | 2010-10-14 | Giordano John A | Kits and methods for nutrition supplementation |
US20080050454A1 (en) * | 2004-08-12 | 2008-02-28 | Giordano John A | Compositions and methods for nutrition supplementation |
US10201560B2 (en) | 2004-08-12 | 2019-02-12 | Exeltis Usa, Inc. | Compositions and methods for nutrition supplementation |
US8609629B2 (en) | 2004-08-12 | 2013-12-17 | Evertt Laboratories, Inc. | Kits and methods for nutrition supplementation |
US10265343B2 (en) | 2004-08-12 | 2019-04-23 | Exeltis Usa, Inc. | Kits and methods for nutrition supplementation |
US20080311200A1 (en) * | 2004-09-17 | 2008-12-18 | Bioprogress S.P.A. | Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8197854B2 (en) | 2005-08-04 | 2012-06-12 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263667B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US20080057144A1 (en) * | 2006-09-01 | 2008-03-06 | Cathy Beggan | Wake up on time dietary supplement and method of use |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8545896B2 (en) | 2011-09-29 | 2013-10-01 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
DE102011122250A1 (en) * | 2011-10-24 | 2013-04-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Multiphase system, useful e.g. to treat vitamin deficiency, comprises two different phases/layers comprising first phase/layer of active component comprising iron(II) compound, and second phase/layer of active component comprising vitamin |
US10034899B2 (en) | 2013-11-27 | 2018-07-31 | BioPharmX, Inc. | Solid oral dosage form for breast symptoms |
Also Published As
Publication number | Publication date |
---|---|
US6488956B1 (en) | 2002-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6488956B1 (en) | Multi-vitamin and mineral supplements for women | |
US5869084A (en) | Multi-vitamin and mineral supplements for women | |
US6299896B1 (en) | Multi-vitamin and mineral supplement | |
US6953588B2 (en) | Multi-vitamin and mineral supplement | |
US6228388B1 (en) | Multi-vitamin and mineral supplement for pregnant women | |
US6361800B1 (en) | Multi-vitamin and mineral supplement | |
US5364644A (en) | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders | |
US5879698A (en) | Calcium dietary supplement | |
US6245360B1 (en) | Nutritional supplement | |
US20020155163A1 (en) | Integrated multi-vitamin and mineral combination | |
JP5349752B2 (en) | Micronutrient supplements | |
US6818228B1 (en) | Dietary supplements containing ultradense calcium citrate and carbonyl iron | |
US6565891B1 (en) | Nutritional supplement for children | |
US8728535B2 (en) | Nutritional supplement for use under physiologically stressful conditions | |
US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
US8263667B2 (en) | Nutritional supplement for use under physiologically stressful conditions | |
US6696083B1 (en) | Vitamin/nutrient dosage regimentation | |
WO2000007463A1 (en) | Multi-vitamin and mineral supplements for women | |
US20030096018A1 (en) | Multi-vitamin and hormone replacement supplement | |
CN102578572A (en) | Mineral and vitamin nutritional supplement | |
US20030045510A1 (en) | Estrogen-plus | |
CA2478278C (en) | Micronutrient supplement | |
Goodhart | Rational use of vitamins in the practice of medicine | |
AT17839U1 (en) | Composition against iron deficiency | |
MXPA99000265A (en) | Dietetic supplements containing calcium citrate and carbonil iron |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |